Day Case Lumbar Fusion Surgery
The study evaluated the short-term clinical efficacy of percutaneous endoscopic posterior lumbar interbody fusion (Endo-LIF) in treating obese patients with lumbar degenerative diseases (LDD). Patients who underwent single-level lumbar fusion surgery were analyzed retrospectively, with the main inclusion criterion being a body mass index (BMI) ≥30 kg/m². The study compared the outcomes between Endo-LIF and transforaminal lumbar interbody fusion (TLIF) in obese patients through a matched case-control design. The results showed that the Endo-LIF group had less blood loss, faster postoperative ambulation, fewer complications, and shorter hospitalization days compared to the TLIF group, although it had a longer operation time and increased x-ray exposure. Both surgeons and patients expressed greater satisfaction with the Endo-LIF procedure. The study concludes that although Endo-LIF requires more time and exposure, it is a safe and effective option for obese patients with LDD
Summarised by Mr Mo Akmal – Lead Spinal Surgeon
The London Spine Unit : most experienced spinal centre in London
Published article
CONCLUSION: Endo-LIF is a safe and effective surgery in the treatment of obese patients. Although this procedure needs longer operation time and x-ray exposure times, it still maybe a promising option for obese patients with LDD.
Lumbar Fusion Surgery Expert. Best Spinal Surgeon UK
Neurochirurgie. 2023 Aug 8:101479. doi: 10.1016/j.neuchi.2023.101479. Online ahead of print.ABSTRACTOBJECTIVE: This study aimed to evaluate short-term clinical efficacy of percutaneous endoscopic posterior lumbar interbody fusion (Endo-LIF) in the treatment of obese patients with lumbar degenerative diseases (LDD).METHODS: Patients who underwent single-level lumbar fusion surgery from July 2020 to July 2022 were retrospectively analyzed in this,
Neurochirurgie. 2023 Aug 8:101479. doi: 10.1016/j.neuchi.2023.101479. Online ahead of print.
ABSTRACT
OBJECTIVE: This study aimed to evaluate short-term clinical efficacy of percutaneous endoscopic posterior lumbar interbody fusion (Endo-LIF) in the treatment of obese patients with lumbar degenerative diseases (LDD).
METHODS: Patients who underwent single-level lumbar fusion surgery from July 2020 to July 2022 were retrospectively analyzed in this study. The main inclusion criterion was a body mass index (BMI) ≥30kg/m2. A matched case-control design was conducted to compare the short-term outcomes between the Endo-LIF and transforaminal lumbar interbody fusion (TLIF) in obese patients. Cases were defined as those who underwent Endo-LIF, and controls were matched from those patients with open TLIF according to corresponding matched criteria. Surgeon satisfaction was evaluated by questionnaires at the end of each surgery, patient satisfaction and their willingness to undergo the same surgery again were collected.
RESULTS: Two groups of patients were successfully completed surgery. In comparison with the open TLIF group, the Endo-LIF group had significantly less blood loss, less time to postoperative ambulation, less postoperative complications and shorter hospitalization days, but longer operation time and x-ray exposure times. The satisfaction of surgeons and patients in Endo-LIF group significantly were superior to open TLIF group.
CONCLUSION: Endo-LIF is a safe and effective surgery in the treatment of obese patients. Although this procedure needs longer operation time and x-ray exposure times, it still maybe a promising option for obese patients with LDD.
PMID:37562539 | DOI:10.1016/j.neuchi.2023.101479
The London Spine Unit : most experienced spinal centre in London
Read the original publication:
Which surgery is better for obese patients with lumbar degenerative diseases: open TLIF or Endo-LIF? A retrospective matched case-control study
